Clinical Trials

Acromegaly

Displaying 3 studies

A Study to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly Rochester, MN

The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Anticipate approximately 70 patients enrolled from start in this trial and approximately 70 patients to roll-over from trial NCT04076462.
A Study to Assess Effectiveness and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly Rochester, MN

The purpose of this study is to assess the effectiveness and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly Rochester, MN

The purpose of this study is to evaluate the safety and effectiveness of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.